Sarah Maguire

Company: AilseBio

Job title: Chief Scientific Officer

Seminars:

How Personalised Should Neoantigen-Targeted Cell Therapies & Cancer Vaccines Be? Unravelling the Limitations of Precision Neoantigen Therapies & Exploring Shared-Neoantigens for an Off-The-Shelf Approach 2:30 pm

Personalised therapies hold promise to provide the most optimal treatment plan available to patients, overcoming tumour heterogeneity and resistance. However, identifying specific neoantigens and developing precision therapies incurs a high cost, complex logistical planning, and a lengthy timeframe which is often too great for patients with late-stage disease. As such, the feasibility and scalability of…Read more

day: Pre-Conference Day

Panel Discussion: Validating Immunogenicity of Neoantigens & Establishing a Consensus on Selecting Optimal Neoantigen Targets to Generate an Efficacious Immune Response 12:00 pm

Developing a robust, functional validation platform using effector T-cells to validate neoantigen immunogenicity and avoid systemic toxicity Establishing a consensus on the most appropriate tools and technologies for ranking and selecting the best neoantigens for targeting Characterising neoantigens and selecting an appropriate number for use in therapies to invoke immunogenicity in patientsRead more

day: Day One